CO5700781A2 - Agonistas morfolinicos de la dopamina - Google Patents
Agonistas morfolinicos de la dopaminaInfo
- Publication number
- CO5700781A2 CO5700781A2 CO05056566A CO05056566A CO5700781A2 CO 5700781 A2 CO5700781 A2 CO 5700781A2 CO 05056566 A CO05056566 A CO 05056566A CO 05056566 A CO05056566 A CO 05056566A CO 5700781 A2 CO5700781 A2 CO 5700781A2
- Authority
- CO
- Colombia
- Prior art keywords
- morpholinic
- dopamine
- agonists
- alkyl
- formulas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
1.- Los compuestos de las fórmulas (I), (Ia) y (Ib) en las que:A se selecciona entre C-X y N, B se selecciona entre C-Y y N, R1 se selecciona entre H y alquilo C1-C6, R2 se selecciona entre H y alquilo C1-C6, X se selecciona entre H, HO, C(O)NH2, NH2, Y se selecciona entre H, HO, NH2, Br, CI y F, Z se selecciona entre H, HO, F, CONH2 y CN;y sus sales, solvatos y profármacos farmacéuticamente aceptables;con las condiciones de que:para un compuesto de la fórmula (I), (la) o (lb), cuando A es C-X, B es C-Y, R1 es H o alquilo C1-C6, y R2 es H o alquilo C1-C6, al menos uno de X, Y y Z debe ser OH;para un compuesto de la fórmula (I), cuando A es C-X y B es C-Y, Y es H, Z es H, R1 es H, y R2 es H, entonces X no puede ser OH.2.- Los compuestos de las fórmulas (I), (la) y (lb) según la reivindicación 1, en las que A es C-X o N y B es C - Y. 3.- Los compuestos de las fórmulas (I), (la) y (lb) según las reivindicaciones 1-2, en las que R1 es H, metilo y etilo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0228787A GB0228787D0 (en) | 2002-12-10 | 2002-12-10 | Morpholine dopamine agonists |
| GB0308460A GB0308460D0 (en) | 2003-04-11 | 2003-04-11 | Morpholine dopamine agonists |
| GB0313606A GB0313606D0 (en) | 2003-06-12 | 2003-06-12 | Morpholine dopamine agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5700781A2 true CO5700781A2 (es) | 2006-11-30 |
Family
ID=32512061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05056566A CO5700781A2 (es) | 2002-12-10 | 2005-06-10 | Agonistas morfolinicos de la dopamina |
Country Status (37)
| Country | Link |
|---|---|
| EP (1) | EP1572214B1 (es) |
| JP (3) | JP3889775B2 (es) |
| KR (1) | KR100796102B1 (es) |
| AP (1) | AP2005003325A0 (es) |
| AR (1) | AR042339A1 (es) |
| AT (1) | ATE460938T1 (es) |
| AU (1) | AU2003302878B2 (es) |
| CA (1) | CA2508262C (es) |
| CO (1) | CO5700781A2 (es) |
| CR (1) | CR7869A (es) |
| CY (1) | CY1110130T1 (es) |
| DE (1) | DE60331769D1 (es) |
| DK (1) | DK1572214T3 (es) |
| EA (1) | EA009589B1 (es) |
| EC (1) | ECSP055850A (es) |
| ES (1) | ES2339767T3 (es) |
| GE (1) | GEP20074272B (es) |
| HK (1) | HK1081850A1 (es) |
| HN (1) | HN2003000401A (es) |
| HR (1) | HRP20050523A2 (es) |
| IS (1) | IS7843A (es) |
| MA (1) | MA27605A1 (es) |
| MX (1) | MXPA05006151A (es) |
| MY (1) | MY144338A (es) |
| NL (1) | NL1024983C2 (es) |
| NO (1) | NO330143B1 (es) |
| NZ (1) | NZ540505A (es) |
| OA (1) | OA13014A (es) |
| PA (1) | PA8591601A1 (es) |
| PE (1) | PE20040906A1 (es) |
| PL (1) | PL377480A1 (es) |
| PT (1) | PT1572214E (es) |
| RS (1) | RS51442B (es) |
| SI (1) | SI1572214T1 (es) |
| TW (1) | TW200423944A (es) |
| UY (1) | UY28117A1 (es) |
| WO (1) | WO2004052372A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2568050A1 (en) * | 2004-05-26 | 2005-12-08 | Pfizer, Inc. | Indazole and indolone derivatives and their use as pharmaceuticals |
| AU2005247699A1 (en) * | 2004-05-27 | 2005-12-08 | Pfizer Inc. | Aminopyridine derivatives as selective dopamine D3 agonists |
| GB0502509D0 (en) * | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
| TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
| GB0700786D0 (en) * | 2007-01-15 | 2007-02-21 | Pfizer Ltd | Morpholine dopamine agonists for the treatment of pain |
| ES2546492T3 (es) | 2010-05-21 | 2015-09-24 | Research Triangle Institute | Derivados de 1-fenilmorfolina como análogos de hidroxibupropion para tratar drogodependencia |
| ES2687095T3 (es) | 2010-05-21 | 2018-10-23 | Research Triangle Institute | Fenilimorfolinas y análogos de las mismas |
| CN105793430B (zh) | 2013-12-11 | 2020-03-03 | 豪夫迈·罗氏有限公司 | 用于制备手性2-芳基吗啉的方法 |
| GB2543296A (en) | 2015-10-13 | 2017-04-19 | Indivior Uk Ltd | Dopamine D3 receptor antagonists having a morpholine moiety |
| EP3725768A1 (en) * | 2019-04-17 | 2020-10-21 | Newron Pharmaceuticals S.p.A. | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB851311A (en) * | 1958-04-02 | 1960-10-12 | Geigy Ag J R | Morpholine compounds and their production |
| GB9108629D0 (en) * | 1991-04-23 | 1991-06-12 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
| GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
-
2003
- 2003-12-02 WO PCT/IB2003/005683 patent/WO2004052372A1/en active Application Filing
- 2003-12-02 DK DK03812639.7T patent/DK1572214T3/da active
- 2003-12-02 DE DE60331769T patent/DE60331769D1/de not_active Expired - Lifetime
- 2003-12-02 NZ NZ540505A patent/NZ540505A/en not_active IP Right Cessation
- 2003-12-02 KR KR1020057010474A patent/KR100796102B1/ko not_active IP Right Cessation
- 2003-12-02 AT AT03812639T patent/ATE460938T1/de active
- 2003-12-02 OA OA1200500171A patent/OA13014A/en unknown
- 2003-12-02 AP AP2005003325A patent/AP2005003325A0/xx unknown
- 2003-12-02 JP JP2005502342A patent/JP3889775B2/ja not_active Expired - Fee Related
- 2003-12-02 PL PL377480A patent/PL377480A1/pl not_active Application Discontinuation
- 2003-12-02 GE GEAP20038838A patent/GEP20074272B/en unknown
- 2003-12-02 EP EP03812639A patent/EP1572214B1/en not_active Expired - Lifetime
- 2003-12-02 ES ES03812639T patent/ES2339767T3/es not_active Expired - Lifetime
- 2003-12-02 MX MXPA05006151A patent/MXPA05006151A/es active IP Right Grant
- 2003-12-02 PT PT03812639T patent/PT1572214E/pt unknown
- 2003-12-02 CA CA002508262A patent/CA2508262C/en not_active Expired - Fee Related
- 2003-12-02 RS YUP-2005/0445A patent/RS51442B/en unknown
- 2003-12-02 EA EA200500801A patent/EA009589B1/ru not_active IP Right Cessation
- 2003-12-02 AU AU2003302878A patent/AU2003302878B2/en not_active Ceased
- 2003-12-02 SI SI200331801T patent/SI1572214T1/sl unknown
- 2003-12-05 PE PE2003001234A patent/PE20040906A1/es not_active Application Discontinuation
- 2003-12-08 MY MYPI20034690A patent/MY144338A/en unknown
- 2003-12-09 AR ARP030104524A patent/AR042339A1/es unknown
- 2003-12-09 TW TW092134694A patent/TW200423944A/zh unknown
- 2003-12-09 HN HN2003000401A patent/HN2003000401A/es unknown
- 2003-12-10 UY UY28117A patent/UY28117A1/es not_active Application Discontinuation
- 2003-12-10 PA PA20038591601A patent/PA8591601A1/es unknown
- 2003-12-10 NL NL1024981A patent/NL1024983C2/nl not_active IP Right Cessation
-
2005
- 2005-05-12 IS IS7843A patent/IS7843A/is unknown
- 2005-05-26 NO NO20052557A patent/NO330143B1/no not_active IP Right Cessation
- 2005-06-09 HR HR20050523A patent/HRP20050523A2/hr not_active Application Discontinuation
- 2005-06-10 EC EC2005005850A patent/ECSP055850A/es unknown
- 2005-06-10 CR CR7869A patent/CR7869A/es unknown
- 2005-06-10 CO CO05056566A patent/CO5700781A2/es not_active Application Discontinuation
- 2005-06-10 MA MA28324A patent/MA27605A1/fr unknown
-
2006
- 2006-02-17 HK HK06102107.0A patent/HK1081850A1/xx not_active IP Right Cessation
- 2006-06-06 JP JP2006157609A patent/JP3920908B2/ja not_active Expired - Fee Related
- 2006-12-27 JP JP2006352505A patent/JP4624341B2/ja not_active Expired - Fee Related
-
2010
- 2010-04-26 CY CY20101100367T patent/CY1110130T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5700781A2 (es) | Agonistas morfolinicos de la dopamina | |
| ES2509820T3 (es) | Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer | |
| ES2485867T3 (es) | Compuestos opioides de carboxamido | |
| ES2500068T3 (es) | Inhibidores heterocíclicos de MEK y métodos de uso de los mismos | |
| ES2528797T3 (es) | Compuestos de aza-benzotiofenilo y métodos de uso | |
| ES2193990T3 (es) | Derivados de purina. | |
| HN2002000156A (es) | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. | |
| AR047823A1 (es) | Derivados de 1,2,3,4-tetrahidroisoquinolina sustituida | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| UY26727A1 (es) | Derivados de tropano útiles en terapia | |
| CR9690A (es) | 3-acilaminobenzanilidas insecticidas | |
| HK1069827A1 (en) | Pyranones useful as atm inhibitors. | |
| AR057464A1 (es) | Procedimiento para la preparacion de derivados de sulfonamida | |
| RS53063B (en) | MGLU2 AGONISTS | |
| AR036602A1 (es) | Agonistas muscarinicos | |
| AR044175A1 (es) | Compuestos de cefemo | |
| DOP2003000764A (es) | Agonistas morfolinicos de la dopamina | |
| EA200201023A1 (ru) | Ингибитор натрий-водородного обмена типа 1(nhe-1) | |
| ES2190781T3 (es) | Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano. | |
| AR046673A1 (es) | Derivados de difenilamina | |
| CU23428A3 (es) | Derivados morfolínicos para uso como agonistas de la dopamina en el tratamiento de la disfunción sexual entre otras | |
| CO5040081A1 (es) | Nuevos compuestos vidad farmaaceutica | |
| ES2188278T3 (es) | Derivados de 3-(heterociclil)-benzoilpirazol. | |
| ECSP972238A (es) | Benzotiofenos amorfos, procedimientos para su preparacion y procedimiento para su uso | |
| BR0317102A (pt) | Derivados de morfolina para utilização como agonistas da dopamina no tratamento da disfunção sexual i.a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted | ||
| FD | Application lapsed |